[
  {
    "ts": "2025-11-12T15:01:31+00:00",
    "headline": "Compugen Ltd (CGEN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges",
    "summary": "Compugen Ltd (CGEN) showcases promising drug discovery initiatives and strategic partnerships, despite facing revenue declines and trial delays.",
    "url": "https://finance.yahoo.com/news/compugen-ltd-cgen-q3-2025-150131590.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "46bfcef2-265d-3973-8744-d79c3c1c51cd",
      "content": {
        "id": "46bfcef2-265d-3973-8744-d79c3c1c51cd",
        "contentType": "STORY",
        "title": "Compugen Ltd (CGEN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges",
        "description": "",
        "summary": "Compugen Ltd (CGEN) showcases promising drug discovery initiatives and strategic partnerships, despite facing revenue declines and trial delays.",
        "pubDate": "2025-11-12T15:01:31Z",
        "displayTime": "2025-11-12T15:01:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/61914a1f03c18992a1b7e52a0ee9d4b4",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jfVxUI8J3HQlvi8IrIFINw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/61914a1f03c18992a1b7e52a0ee9d4b4.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_cpx9J8_h04piTpuVXS24g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/61914a1f03c18992a1b7e52a0ee9d4b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/compugen-ltd-cgen-q3-2025-150131590.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/compugen-ltd-cgen-q3-2025-150131590.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CGEN"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-12T21:01:00+00:00",
    "headline": "MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress",
    "summary": "Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platformRealigned pipeline priorities by ending development of lorigerlimab in prostate cancer while continuing development in ovarian cancerCash runway guidance extended into late 2027 ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on devel",
    "url": "https://finance.yahoo.com/news/macrogenics-reports-third-quarter-2025-210100888.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "6e599cd2-9e43-39bb-bcf1-5990b09943d7",
      "content": {
        "id": "6e599cd2-9e43-39bb-bcf1-5990b09943d7",
        "contentType": "STORY",
        "title": "MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress",
        "description": "",
        "summary": "Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platformRealigned pipeline priorities by ending development of lorigerlimab in prostate cancer while continuing development in ovarian cancerCash runway guidance extended into late 2027 ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on devel",
        "pubDate": "2025-11-12T21:01:00Z",
        "displayTime": "2025-11-12T21:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/97a0c0c0b8a51ff25869dc61e9f9420e",
          "originalWidth": 1200,
          "originalHeight": 694,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l302YrLd20ZHOIwyTgnK0Q--~B/aD02OTQ7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/97a0c0c0b8a51ff25869dc61e9f9420e.cf.webp",
              "width": 1200,
              "height": 694,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DBWbKz85yc_jfzB25TjRbQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/97a0c0c0b8a51ff25869dc61e9f9420e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/macrogenics-reports-third-quarter-2025-210100888.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/macrogenics-reports-third-quarter-2025-210100888.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MGNX"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "SAN.PA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]